AlphaTON's 15min chart shows MACD Death Cross, Bollinger Bands Narrowing, KDJ Death Cross.

The 15-minute chart for AlphaTON recently exhibited a MACD Death Cross, a narrowing of Bollinger Bands, and a KDJ Death Cross at 09/26/2025 13:00. This suggests that the stock price is likely to continue trending downwards, with a decrease in the magnitude of price fluctuations and a shift in momentum towards the downside, potentially leading to further decreases in the stock price.

Onconetix Inc. (ONCO), a commercial-stage biotech innovator, has been navigating a series of regulatory and strategic challenges in recent months. The company has faced delisting threats from Nasdaq due to compliance issues, including late filings and low share prices. Despite these challenges, Onconetix has taken proactive measures to address these concerns and maintain its market position.

On September 26, 2025, Onconetix announced the termination of its merger agreement with Ocuvex Therapeutics, a private biopharmaceutical company. The termination comes after the companies signed a definitive merger agreement in July 2025, which was expected to combine Ocuvex's pipeline of commercial and late clinical stage ophthalmic assets with Onconetix's public market presence. The termination of the merger agreement has been attributed to strategic differences and may impact Onconetix's future growth prospects Onconetix Stock Price, News & Analysis^[1].

Earlier in the year, Onconetix faced delisting threats from Nasdaq due to non-compliance with the minimum bid price requirement and late filings of its 10-Q and 10-K reports. The company has since taken steps to address these issues, including a 1-for-85 reverse stock split and the submission of its Form 10-Q report. However, the company's stock price has continued to decline, and it remains to be seen if these measures will be sufficient to avoid delisting .

Despite these challenges, Onconetix has been making progress in its clinical research and product development. The company's subsidiary, Proteomedix, has entered into a licensing agreement with Immunovia for the manufacturing of key reagents used in their pancreatic cancer test PancreaSure. This agreement is expected to generate significant revenue for Onconetix and further its mission to develop innovative therapies for men's health and oncology .

In conclusion, Onconetix Inc. faces a challenging road ahead, with regulatory compliance and strategic moves playing a significant role in shaping the company's future. As the company continues to navigate these challenges, investors should closely monitor Onconetix's progress and the potential impact of these developments on the company's stock price.